Treatment of meningitis caused by vancomycin-resistant Enterococcus faecium: High-dose and combination daptomycin therapy

Annals of Pharmacotherapy

Volumn 44, Issue 12, 2010, Pages 2001-2006

  Le, Jennifer ^a   Bookstaver, P Brandon ^b   Rudisill, Celeste N ^b   Hashem, Mohamed G ^c   Iqbal, Raza ^d   James, Charles L ^a,e,f   Sakoulas, George ^g  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF SOUTH CAROLINA   (United States)

^c Medco Health Solutions   (United States)

^d LONG BEACH MEMORIAL MEDICAL CENTER   (United States)

^e UCSD MEDICAL CENTER   (United States)

^f University School of Medicine   (United States)

^g UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

Cerebrospinal fluid shunt infections; Daptomycin; Meningitis; Vancomycin resistant Enterococcus

Indexed keywords

AMPICILLIN; CEFTRIAXONE; CHLORAMPHENICOL; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; GENTAMICIN; LINEZOLID; PIPERACILLIN PLUS TAZOBACTAM; VANCOMYCIN;

ABSCESS; ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL MENINGITIS; BRAIN VENTRICLE PERITONEUM SHUNT; CASE REPORT; CEREBROSPINAL FLUID EXAMINATION; CRANIOTOMY; CREATINE KINASE BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG MEGADOSE; DRUG POTENTIATION; DRUG WITHDRAWAL; ENTEROCOCCAL INFECTION; ENTEROCOCCUS FAECIUM; HUMAN; HYDROCEPHALUS; HYGROMA; KIDNEY INJURY; MALE; MINIMUM INHIBITORY CONCENTRATION; NERVE DECOMPRESSION; PARASPINAL ABSCESS; PRIORITY JOURNAL; SIDE EFFECT; TRIGEMINAL NERVE; VANCOMYCIN RESISTANT ENTEROCOCCUS;

ACETAMIDES; AGED; DAPTOMYCIN; DRUG THERAPY, COMBINATION; ENTEROCOCCUS FAECIUM; GENTAMICINS; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; MALE; MENINGITIS, BACTERIAL; MIDDLE AGED; OXAZOLIDINONES; VANCOMYCIN; VANCOMYCIN RESISTANCE;

EID: 78649951366     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1P333     Document Type: Article

References (53)

1. Tunkel AR, Drake JM. Cerebrospinal fluid shunt infections. In: Mandell GL, Bennett JE, Dolin R, eds. Principles and practice of infectious diseases. 7th ed. Philadelphia: Elsevier, Inc., 2010:1231-6.
2. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control 2004;32:470-85. DOI 10.1016/S0196655304005425
3. Hidron AI, Edwards JR, Patel J, et al. NHSN annual update: antimicrobial- resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007. Infect Control Hosp Epidemiol 2008;29:996-1011. DOI 10.1086/591861
4. Lee DH, Palermo B, Chowdhury M. Successful treatment of methicillin-resistant Staphylococcus aureus meningitis with daptomycin. Clin Infect Dis 2008;47:588-90. DOI 10.1086/590257
5. Jenkins I. Linezolid- and vancomycin-resistant Enterococcus faecium endocarditis: successful treatment with tigecycline and daptomycin. J Hosp Med 2007;2:343-4. DOI 10.1002/jhm.236
6. Gallagher JC, Perez ME, Marino EA, LoCastro LG, Abrardo LA, MacDougall C. Daptomycin therapy for vancomycin-resistant enterococcal bacteremia: a retrospective case series of 30 patients. Pharmacotherapy 2009;29:792-9. DOI 10.1592/phco.29.7.792
7. Elvy J, Porter D, Brown E. Treatment of external ventricular drain-associated ventriculitis caused by Enterococcus faecalis with intraventricular daptomycin. J Antimicrob Chemother 2008;61:461-2. DOI 10.1093/jac/dkm501
8. Jaspan HB, Brothers AW, Campbell AJ, et al. Multidrug-resistant Enterococcus faecium meningitis in a toddler: characterization of the organism and successful treatment with intraventricular daptomycin and intravenous tigecycline. Pediatr Infect Dis J 2009;29:379-81. DOI 10.1097/INF. 0b013e3181c806d8
9. Allen GP, Cha R, Rybak MJ. In vitro activities of quinupristin-dalfo- pristin and cefepime, alone and in combination with various antimicrobials, against multidrug-resistant staphylococci and enterococci in an in vitro pharmacodynamic model. Antimicrob Agents Chemother 2002;46: 2606-12.
10. Bain KT, Wittbrodt ET. Linezolid for the treatment of resistant gram-positive cocci. Ann Pharmacother 2001;35:566-75. DOI 10.1345/aph.10276
11. Caron F, Kitzis MD, Gutmann L, et al. Daptomycin or teicoplanin in combination with gentamicin for treatment of experimental endocarditis due to a highly glycopeptide-resistant isolate of Enterococcus faecium. Antimicrob Agents Chemother 1992;36:2611-6.
12. Cilli F, Aydemir S, Tunger A. In vitro activity of daptomycin alone and in combination with various antimicrobials against gram-positive cocci. J Chemother 2006;18:27-32.
13. Eliopoulos GM, Wennersten CB. Antimicrobial activity of quinupristin-dalfopristin combined with other antibiotics against vancomycin-resistant enterococci. Antimicrob Agents Chemother 2002;46:1319-24.
14. Gill CJ, Murphy MA, Hamer DH. Treatment of Staphylococcus epidermidis ventriculo-peritoneal shunt infection with linezolid. J Infect 2002; 45:129-32. DOI S0163445302909795
15. Kang SL, Rybak MJ. In-vitro bactericidal activity of quinupristin/dalfo- pristin alone and in combination against resistant strains of Enterococcus species and Staphylococcus aureus. J Antimicrob Chemother 1997; 39(suppl A):33-9.
16. Matsumura SO, Louie L, Louie M, Simor AE. Synergy testing of vancomycin- resistant Enterococcus faecium against quinupristin-dalfopristin in combination with other antimicrobial agents. Antimicrob Agents Chemother 1999;43:2776-9.
17. Mercier RC, Kennedy C, Meadows C. Antimicrobial activity of tigecycline (GAR-936) against Enterococcus faecium and Staphylococcus aureus used alone and in combination. Pharmacotherapy 2002;22:1517-23.
18. Messick CR, Rodvold KA, Pendland SL. Modified time-kill assay against multidrug-resistant Enterococcus faecium with novel antimicrobial combinations. J Antimicrob Chemother 1999;44:831-4.
19. Pankey G, Ashcraft D, Patel N. In vitro synergy of daptomycin plus rifampin against Enterococcus faecium resistant to both linezolid and vancomycin. Antimicrob Agents Chemother 2005;49:5166-8. DOI 10.1128/AAC.49.12. 5166-5168.2005
20. Patel R, Rouse MS, Piper KE, Steckelberg JM. In vitro activity of GAR- 936 against vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus and penicillin-resistant Streptococcus pneumoniae. Diagn Microbiol Infect Dis 2000;38:177-9. DOI S0732-8893(00)00193-0
21. Saravolatz LD, Stein GE, Johnson LB. Telavancin: a novel lipoglycopeptide. Clin Infect Dis 2009;49:1908-14. DOI 10.1086/648438
22. Miranda J, Tunkel AR. Strategies and new developments in the management of bacterial meningitis. Infect Dis Clin North Am 2009;23:925-43, viii-ix. DOI 10.1016/j.idc.2009.06.014
23. Rose WE, Rybak MJ, Kaatz GW. Evaluation of daptomycin treatment of Staphylococcus aureus bacterial endocarditis: an in vitro and in vivo simulation using historical and current dosing strategies. J Antimicrob Chemother 2007;60:334-40. DOI 10.1093/jac/dkm170
24. Rose WE, Leonard SN, Rybak MJ. Evaluation of daptomycin pharmacodynamics and resistance at various dosage regimens against Staphylococcus aureus isolates with reduced susceptibilities to daptomycin in an in vitro pharmacodynamic model with simulated endocardial vegetations. Antimicrob Agents Chemother 2008;52:3061-7. DOI 10.1128/AAC.00102-08
25. Cotroneo N, Harris R, Perlmutter N, Beveridge T, Silverman JA. Daptomycin exerts bactericidal activity without lysis of Staphylococcus aureus. Antimicrob Agents Chemother 2008;52:2223-5. DOI 10.1128/AAC.01410-07
26. Stucki A, Cottagnoud M, Winkelmann V, Schaffner T, Cottagnoud P. Daptomycin produces an enhanced bactericidal activity compared to ceftriaxone, measured by [3H]choline release in the cerebrospinal fluid, in experimental meningitis due to a penicillin-resistant pneumococcal strain without lysing its cell wall. Antimicrob Agents Chemother 2007;51: 2249-52. DOI 10.1128/AAC.01000-06
27. Cottagnoud P, Pfister M, Acosta F, et al. Daptomycin is highly efficacious against penicillin-resistant and penicillin- and quinolone-resistant pneumococci in experimental meningitis. Antimicrob Agents Chemother 2004;48:3928-33. DOI 10.1128/AAC.48.10.3928-3933.2004
28. Grandgirard D, Oberson K, Buhlmann A, Gaumann R, Leib SL. Attenuation of cerebrospinal fluid inflammation by the nonbacteriolytic antibiotic daptomycin versus that by ceftriaxone in experimental pneumococcal meningitis. Antimicrob Agents Chemother 2010;54:1323-6. DOI 10.1128/AAC.00812-09
29. Gerber P, Stucki A, Acosta F, Cottagnoud M, Cottagnoud P. Daptomycin is more efficacious than vancomycin against a methicillin-susceptible Staphylococcus aureus in experimental meningitis. J Antimicrob Chemother 2006;57:720-3. DOI 10.1093/jac/dkl007
30. Egermann U, Stanga Z, Ramin A, et al. Combination of daptomycin plus ceftriaxone is more active than vancomycin plus ceftriaxone in experimental meningitis after addition of dexamethasone. Antimicrob Agents Chemother 2009;53:3030-3. DOI 10.1128/AAC.00952-08
31. Riser MS, Bland CM, Rudisill CN, Bookstaver PB. Cerebrospinal fluid penetration of high-dose daptomycin in suspected Staphylococcus aureus meningitis. Ann Pharmacother 2010;44:1832-5. DOI 10.1345/aph.1P307
32. Alou L, Aguilar L, Gimenez MJ, Torrico M, Sevillano D. Activity of serum concentrations of daptomycin vs vancomycin against vancomycin- susceptible and resistant Enterococcus faecium in the presence of albumin physiological concentrations: an in vitro pharmacodynamic simulation. Eur J Clin Microbiol Infect Dis 2008;27:1009-11. DOI 10.1007/s10096-008-0525-3
33. Moise PA, Hershberger E, Amodio-Groton MI, Lamp KC. Safety and clinical outcomes when utilizing high-dose (≥ mg/kg) daptomycin therapy. Ann Pharmacother 2009;43:1211-9. DOI 10.1345/aph.1M085
34. Figueroa DA, Mangini E, Amodio-Groton M, et al. Safety of high-dose intravenous daptomycin treatment: three-year cumulative experience in a clinical program. Clin Infect Dis 2009;49:177-80. DOI 10.1086/600039
35. Benvenuto M, Benziger DP, Yankelev S, Vigliani G. Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers. Antimicrob Agents Chemother 2006;50:3245-9. DOI 10.1128/AAC.00247-06
36. Wise R, Gee T, Andrews JM, Dvorchik B, Marshall G. Pharmacokinetics and inflammatory fluid penetration of intravenous daptomycin in volunteers. Antimicrob Agents Chemother 2002;46:31-3. (Pubitemid 34031598)
37. LaPlante KL, Rybak MJ. Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model. Antimicrob Agents Chemother 2004;48:4665-72. DOI 10.1128/AAC.48.12.4665-4672.2004
38. Gavalda J, Cardona PJ, Almirante B, et al. Treatment of experimental endocarditis due to Enterococcus faecalis using once-daily dosing regimen of gentamicin plus simulated profiles of ampicillin in human serum. Antimicrob Agents Chemother 1996;40:173-8.
39. Gavalda J, Onrubia PL, Gomez MT, et al. Efficacy of ampicillin combined with ceftriaxone and gentamicin in the treatment of experimental endocarditis due to Enterococcus faecalis with no high-level resistance to aminoglycosides. J Antimicrob Chemother 2003;52:514-7. DOI 10.1093/jac/dkg360
40. Graham PL, Ampofo K, Saiman L. Linezolid treatment of vancomycin-resistant Enterococcus faecium ventriculitis. Pediatr Infect Dis J 2002;21: 798-800.
41. Shaikh ZH, Peloquin CA, Ericsson CD. Successful treatment of vancomycin- resistant Enterococcus faecium meningitis with linezolid: case report and literature review. Scand J Infect Dis 2001;33:375-9.
42. Steinmetz MP, Vogelbaum MA, De Georgia MA, Andrefsky JC, Isada C. Successful treatment of vancomycin-resistant enterococcus meningitis with linezolid: case report and review of the literature. Crit Care Med 2001;29:2383-5. (Pubitemid 34038174)
43. Tsai TN, Wu CP, Peng MY, Giian CF, Lee SY, Lu JJ. Short course of linezolid treatment for vancomycin-resistant Enterococcus faecium meningitis. Int J Clin Pract 2006;60:740-1. DOI 10.1111/j.1368-5031.2006.00706.x
44. Zeana C, Kubin CJ, Della-Latta P, Hammer SM. Vancomycin-resistant Enterococcus faecium meningitis successfully managed with linezolid: case report and review of the literature. Clin Infect Dis 2001;33:477-82. DOI 10.1086/321896
45. Webster DP, Griffiths S, Bowler IC. Failure of linezolid therapy for post-neurosurgical meningitis due to Enterococcus faecium. J Antimicrob Chemother 2009;63:622-3. DOI 10.1093/jac/dkn519
46. Seedat J, Zick G, Klare I, Konstabel C, Weiler N, Sahly H. Rapid emergence of resistance to linezolid during linezolid therapy of an Enterococcus faecium infection. Antimicrob Agents Chemother 2006;50:4217-9. DOI 10.1128/AAC.00518-06
47. Swoboda S, Fritz S, Martignoni ME, et al. Varying linezolid susceptibility of vancomycin-resistant Enterococcus faecium isolates during therapy: a case report. J Antimicrob Chemother 2005;56:787-9. DOI 10.1093/jac/dki318
48. Sakoulas G, Moise PA, Nizet V. Ampicillin enhances the activity of daptomycin by alteration of surface charge in vancomycin-resistant Enterococcus faecium. Abstract E-806. 49th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 12, 2009, San Francisco, CA.
49. Entenza JM, Giddey M, Vouillamoz J, Moreillon P. In vitro prevention of the emergence of daptomycin resistance in Staphylococcus aureus and enterococci following combination with amoxicillin/clavulanic acid or ampicillin. Int J Antimicrob Agents 2010;35:451-6. DOI 10.1016/j.ijantimicag.2009.12.022
50. Garrison MW, Mutters R, Dowzicky MJ. In vitro activity of tigecycline and comparator agents against a global collection of gram-negative and gram-positive organisms: Tigecycline Evaluation and Surveillance Trial 2004 to 2007. Diagn Microbiol Infect Dis 2009;65:288-99. DOI 10.1016/j.diagmicrobio. 2009.07.010
51. Abb J. In vitro activities of tigecycline, daptomycin, linezolid and quinupristin/ dalfopristin against glycopeptide-resistant Enterococcus faecium. Int J Antimicrob Agents 2007;29:358-60. DOI 10.1016/j.ijantimicag.2006.10.007
52. Moise PA, Castro RS, Sul C, Forrest A, Sakoulas G. Relationship of line-zolid minimum inhibitory concentration and time to bacterial eradication in treatment for methicillin-resistant Staphylococcus aureus infection (letter). Ann Pharmacother 2008;42:592-3. DOI 10.1345/aph.1K613
53. Jorgensen JH, Crawford SA, Kelly CC, Patterson JE. In vitro activity of daptomycin against vancomycin-resistant enterococci of various Van types and comparison of susceptibility testing methods. Antimicrob Agents Chemother 2003;47:3760-3.